CSF2 and head and neck squamous cell carcinoma: The phase 1 clinical trial of 15 patients with refractory and metastatic HNSCC showed that combination therapy of cyclophosphamide and radiation therapy in combination with GM-CSF (granulocyte macrophage-colony-stimulating factor) could demonstrate significant therapeutic benefit [90].